Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.53 |
| ▸ | TOP2A | P11388 | 1/20 | 0.46 |
| ▸ | TK1 | P04183 | 3/20 | 0.44 |
| ▸ | TK2 | O00142 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7034888 | 1.00 | RNASE1 (0.53) | RNASE1TOP2ATK1TK2LMNA | |
| SCHEMBL7031388 | 0.92 | RNASE1 (0.52) | RNASE1TOP2ATK1TK2 | |
| SCHEMBL7031391 | 0.92 | RNASE1 (0.52) | RNASE1TOP2ATK1TK2 | |
| SCHEMBL7038044 | 0.90 | RNASE1 (0.53) | RNASE1TK1TK2LMNATSHR | |
| SCHEMBL6892320 | 0.87 | RNASE1 (0.56) | RNASE1TOP2ATK1TK2LMNA | |
| SCHEMBL6892317 | 0.85 | RNASE1 (0.54) | RNASE1TOP2ATK1TK2LMNA | |
| SCHEMBL7035273 | 0.83 | TOP2A (0.51) | RNASE1TOP2ATK1TK2 | |
| SCHEMBL7033117 | 0.79 | TOP2A (0.49) | RNASE1TOP2ATK1 | |
| SCHEMBL6572381 | 0.79 | RNASE1 (0.59) | RNASE1TK1TK2ALBPKM | |
| SCHEMBL6573680 | 0.79 | RNASE1 (0.59) | RNASE1TK1TK2ALBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030013868-A1 | C-3' protected monomeric nucleotides and synthesis of oligonucleotides on solid support | LINDEN TECHNOLOGIES, INC., A DELAWARE CORPORATION | 2003-01-16 | — | — | US | disclosed |
| US-20030009027-A1 | C-3' protected monomeric nucleotides and synthesis of oligonucleotides on solid support | LINDEN TECHNOLOGIES, INC., A DELAWARE CORPORATION | 2003-01-09 | — | — | US | disclosed |
| US-6489466-B2 | PRODUCING IMMOBILIZED OLIGONUCLEOTIDES ON A SUBSTRATE BY COVALENTLY ATTACHING A FIRST NUCLEOTIDE OR OLIGONUCLEOTIDE VIA A C-5' OXYGEN OF THE NUCLEOTIDE TO THE SUBSTRATE; C-3'OXYGEN PROTECTED WITH PHOTO- OR CHEMICAL-LABILE GROUPS | LINDEN TECHNOLOGIES, INC. | 2002-12-03 | — | — | US | disclosed |
| US-20010044530-A1 | C-3' protected monomeric nucleotides and synthesis of oligonucleotides on solid support | LINDEN TECHNOLOGIES, INC. | 2001-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013868-A1 | C-3' protected monomeric nucleotides and synthesis of oligonucleotides on solid support | RNGTT, BCDIN3D, NT5C3B | RNASE1 165/4885TOP2A 3198/4885TK1 371/4885 |
| US-20010044530-A1 | C-3' protected monomeric nucleotides and synthesis of oligonucleotides on solid support | RNGTT, BCDIN3D, NT5C3B | RNASE1 165/4885TOP2A 3198/4885TK1 371/4885 |
| US-20030009027-A1 | C-3' protected monomeric nucleotides and synthesis of oligonucleotides on solid support | RNGTT, BCDIN3D, NT5C3B | RNASE1 165/4885TOP2A 3198/4885TK1 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.